Genentech, Inc. (NYSE: DNA) announced that a Roche-sponsored Phase III study evaluating two different doses of Avastin(R) (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy met the primary endpoint of prolonging progression-free survival (PFS) in patients with previously untreated, advanced non-squamous, non-small cell lung cancer (NSCLC), the most common form of the disease.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that it has received a letter from Third Point LLC dated February 22, 2007.
On 22 February 2007 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending to grant a marketing authorisation for the medicinal product Sebivo, 600 mg, film-coated tablet intended for treatment of chronic hepatitis B virus (HBV) infection in adult patients.
Roche announced that it is temporarily suspending recruitment into its Phase II dose-finding study (NH19960) with the investigational drug C.E.R.A. in anaemic patients with advanced non small cell lung cancer receiving chemotherapy.
A draft of proposals which together add up to the loss of professionally-led medical regulation have the potential to muzzle doctors in their role of speaking out for their patients, warns the British Medical Association (BMA).
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
HIV prevention research was responsible for the recent revelation that male circumcision can play an important role in protecting men from infection with the deadly virus.
Voicing serious concern over a proposed Nigerian bill which would effectively outlaw same-sex relationships, four independent United Nations experts today said it would violate international human rights norms, and urged the Government to withdraw it immediately.
Doubts over three influential head injury studies mean that patients are receiving treatment that may be unsound, warn doctors in this week?s BMJ.
In an effort to reach a greater audience, and help patients and their families understand their cancer treatment options, the American Society for Therapeutic Radiology and Oncology now offers Spanish versions of their popular brochures Radiation Therapy for Breast Cancer and Radiation Therapy for Prostate Cancer.